GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Total Liabilities

Peak Bio (Peak Bio) Total Liabilities : $21.11 Mil (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio Total Liabilities?

Peak Bio's Total Liabilities for the quarter that ended in Jun. 2023 was $21.11 Mil.

Peak Bio's quarterly Total Liabilities increased from Dec. 2022 ($15.62 Mil) to Mar. 2023 ($17.05 Mil) and increased from Mar. 2023 ($17.05 Mil) to Jun. 2023 ($21.11 Mil).

Peak Bio's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2021 ($3.01 Mil) and increased from Dec. 2021 ($3.01 Mil) to Dec. 2022 ($15.62 Mil).

Peak Bio Total Liabilities Historical Data

The historical data trend for Peak Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peak Bio Total Liabilities Chart

Peak Bio Annual Data
Trend Dec21 Dec22
Total Liabilities
3.01 15.62

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Liabilities Get a 7-Day Free Trial - 2.39 15.62 17.05 21.11

Peak Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Peak Bio's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.801+(3.507+1.316
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=15.62

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=7.53--8.094
=15.62

Peak Bio's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.013+(0+3.101
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=21.11

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=1.795--19.319
=21.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Peak Bio Total Liabilities Related Terms

Thank you for viewing the detailed overview of Peak Bio's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Peak Bio (Peak Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Total Liabilities
Comparable Companies
NBRVF BXRX AMPE ADTX DRMA SCPS RUBY INM GLMD RVLPQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Website
https://www.peak-bio.com
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019